2021 · Analytical and bioanalytical chemistry · paywalled
Development and validation of a UHPLC-MS/MS method to measure cefotaxime and metabolite desacetylcefotaxime in blood plasma: a pilot study suitable for capillary microsampling in critically ill children
Guerra Valero et al.
The finding, in our words
A UHPLC-MS/MS method was validated for measuring cefotaxime and its metabolite in only 2.8 μL of capillary plasma from critically ill children, achieving precision within ±7.3% and accuracy within ±5% across therapeutic ranges. This enables therapeutic drug monitoring in paediatric populations where large-volume sampling is ethically and physiologically problematic.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This study validated a method requiring only 10 microlitres of serum and found high agreement between fingerstick capillary samples and venous serum for monitoring twelve antibiotics. The results suggest capillary serum sampling is a feasible, minimally invasive alternative that avoids the haematocrit effect associated with whole blood microsampling.
The study developed and validated a rapid LC-MS/MS method for quantifying cefazolin in capillary whole blood collected via VAMS, plasma, and plasma ultrafiltrate, showing robust performance across matrices and successful application in a pediatric pilot cohort for therapeutic drug monitoring.
Kocur et al., Clinica chimica acta; international journal of clinical chemistry (paywalled) · source ↗
The study compared quantitative dried blood spot (qDBS) and volumetric absorptive microsampling (VAMS) devices for measuring ganciclovir levels in capillary blood from pediatric renal transplant recipients. This comparison provides evidence for choosing between microsampling devices in therapeutic drug monitoring, supporting decentralised sampling approaches that reduce patient burden while maintaining analytical accuracy.
Kocur et al., European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (paywalled) · source ↗
The authors validated a UPLC-PDA assay for ceftazidime in 10 microlitre dried blood spots collected with the Capitainer device from neonatal patients, achieving accuracy of 90.1 to 104.8 per cent and precision within 11.7 per cent coefficient of variation across a quantification range of 0.5 to 200 micrograms per millilitre, and confirmed the method worked on clinical neonatal samples. This supports microsampling-based therapeutic drug monitoring of an antimicrobial in a vulnerable population where conventional venous blood draws are difficult.
Lv et al., Journal of pharmaceutical and biomedical analysis (paywalled) · source ↗
A validated high-throughput LC-MS/MS assay for piperaquine from dried blood spots achieved 54-72% recovery with <9% relative standard deviation and a quantification limit of 3 ng/mL, enabling detection for 4-8 weeks post-dose. The method showed minimal haematocrit interference and is suitable for therapeutic drug monitoring of antimalarial treatment in resource-limited settings and pediatric populations.
Blessborn et al., Journal of mass spectrometry and advances in the clinical lab · source ↗